Table 3.
Results of echocardiographic measurement, endothelial injury marker tests and masson staining.
| Group | Control | Model | BMSC | MiR-21 mimics | MiR-21 inhibitors |
|---|---|---|---|---|---|
| LVEF, % | 67.8±6.2 | 42.9±7.8* | 47.5±6.4* | 52.3±5.2*# | 39.3±4.7*@& |
| FS, % | 36.2±2.3 | 22.2±3.9* | 26.9±4.8*# | 29.2±5.2*# | 20.2±4.2*@& |
| LVVs, ml | 2.8±0.3 | 3.8±0.6* | 3.5±0.5* | 3.3±0.5*# | 3.8±0.5*& |
| LVVd, ml | 5.2±0.7 | 6.3±0.4* | 6.0±0.4* | 5.8±0.4*# | 6.4±0.5*& |
| cTnI, pg/ml | 11.68±1.43 | 16.37±2.13* | 15.12±2.08* | 13.55±2.26# | 17.86±2.37*@& |
| h-FABP, ng/ml | 10.35±1.79 | 18.78±2.74* | 17.12±2.69* | 14.57±2.31*#@ | 23.32±3.15*#@& |
| vWF, ng/ml | 4.79±0.87 | 8.15±1.15* | 7.17±1.14*# | 5.82±0.95*#@ | 9.28±1.26*#@& |
| Fibrosis, %LV | 0±0 | 47.71±3.18* | 35.04±4.38*# | 20.36±2.39*#@ | 48.70±3.19*@& |
LVEF – left ventricular ejection fractions; FS – fractional shortening; LVVs – left ventricular end-systolic volume; LVVd – left ventricular end-diastolic volume; cTnI – cardiac troponin I; h-FABP – heart-type fatty acid binding protein; vWF – von Willebrand factor.
*
P<0.05 versus control group;
#
P<0.05 versus NC group;
@
P<0.05 versus BMSC group,
&
P<0.05 versus miR-21 mimics group.